| Literature DB >> 15947743 |
Abstract
Neonates represent a unique and highly vulnerable patient population. Advances in medical technology that have occurred over the last few decades have improved the survival and quality of life for neonates, particularly those infants born with extreme prematurity or with congenital defects. Although immunologic immaturity and altered cutaneous barriers play some role in the vulnerability of neonates to nosocomial infections, clearly, therapeutic interventions that have proven to be lifesaving for these fragile infants also appear to be associated with the majority of infectious complications resulting in neonatal morbidity and mortality. Rates of infections in neonatal intensive care units (NICUs) have varied from 6% to 40% of neonatal patients, with the highest rates in those facilities having larger proportions of very low-birth-weight infants (birthweight < or =1000 grams) or neonates requiring surgery. Efforts to protect the vulnerable NICU infants include the following: (1) optimal infection control practices, especially good hand hygiene and good nursery design; (2) prudent use of invasive interventions with particular attention to early removal of invasive devices after they are no longer essential; and (3) judicious use of antimicrobial agents, with an emphasis on targeted (narrow spectrum) rather than broad-spectrum antibiotics and appropriate indications (proven or suspected bacterial infections).Entities:
Mesh:
Year: 2005 PMID: 15947743 PMCID: PMC7119124 DOI: 10.1016/j.ajic.2004.11.006
Source DB: PubMed Journal: Am J Infect Control ISSN: 0196-6553 Impact factor: 2.918
Quantitative and qualitative immune deficiencies noted in newborn infants5, 6, 7
| Component of the immune system | Defect |
|---|---|
| Phagocytic cells (PMNs and monocytes) | Decreased migration/chemotaxis |
| Decreased phagocytic activity | |
| Decreased bone marrow storage pool of PMNs | |
| B-cells/immunoglobulins | IgM synthesis delayed until 30 weeks gestation |
| Dependence on maternally derived IgG | |
| Poor response to polysaccharide antigens | |
| T lymphocytes | Diminished T-cell-mediated cytotoxicity |
| Diminished participation in delayed-type hypersensitivity | |
| Diminished potentiation of B-cell differentiation | |
| Complement/opsonization | Decreases in both classic and alternate pathways |
| Decreased fibronectin (50% of adult levels) | |
| Natural killer cells | Decreased number |
| Decreased cytotoxicity | |
| Reticuloendothelium | Decreased antigen removal |
Common vertically/natally acquired infections
| Bacteria | Viruses | Other |
|---|---|---|
| Group B | Herpes simplex | |
| Cytomegalovirus | ||
| Gram-negative enteric rods | HIV | |
| Hepatitis B | ||
Microorganisms that may be transmitted through breast milk16, 17
| Microorganism contraindicated | Breastfeeding |
|---|---|
| Cytomegalovirus | No |
| Hepatitis B | No |
| Hepatitis C | No |
| Human immunodeficiency virus (HIV) | Yes |
| Human T-lymphotrophic virus type I (HTLV-I) | Yes |
| Human T-lymphotrophic virus type II (HTLV-II) | Yes |
| Herpes simplex | No |
| Rubella | No |
Mothers who are hepatitis B surface antigen positive (newly acquired infection or chronic carriers) may breastfeed after their infant receives hepatitis B immune globulin (HBIG) within 12 hours of birth and initiates the hepatitis B vaccine series.
Breastfeeding by HIV-infected mothers should be prohibited, unless a safe alternative is not available.
Mothers who have after herpetic lesions on their breasts should refrain from breastfeeding until the lesion has resolved.
National Nosocomial Infection Surveillance (NNIS) bacteremia and pneumonia rates in NICU patients by birth weight3, 32
| Birth weight category | 1990-1995 | 1995-2003 |
|---|---|---|
| ≤1000 grams | 12.1 | 10.6 |
| 1001-1500 grams | 5.7 | 6.4 |
| 1501-2500 grams | 5.0 | 4.1 |
| >2500 grams | 4.1 | 3.7 |
| ≤1000 grams | 3.4 | 3.3 |
| 1001-1500 grams | 2.2 | 2.5 |
| 1501-2500 grams | 1.9 | 2.1 |
| >2500 grams | 1.0 | 1.4 |
Rates are the number of bacteremias per 1000 catheter days.
Rates are the number of pneumonias per 1000 ventilator days.
Exposure prophylaxis for natally acquired infections
| Microorganism agent | Chemoprophylaxis/immunoprophylaxis |
|---|---|
| Erythromycin or silver nitrate eye drops | |
| Group B | Intrapartum ampicillin |
| Hepatitis B | HBIG/hepatitis B vaccine |
| Hepatitis A | Immune serum globulin |
| Varicella Zoster | Varicella Zoster immunoglobulin (VZIG) |
| Human immunodeficiency virus | Antiretroviral therapy for the mother and zidovudine and/or nevirapine for the infant |
| Equivocal benefit for erythromycin | |
| Respiratory syncytial virus | Palivizumab |